title: Concomitant infection of HTLV-I and HIV-1: prevalence of IgG and IgM antibodies in Washington, D.C. area.
abstract: Serum samples collected from four groups of individuals in the Washington, D.C. area were examined for the presence of IgG and IgM classes of antibody reacting against HTLV-I and HIV-1. These four groups were: (1) healthy adults with negative premarital VDRL test for syphilis (n = 113), (2) miscellaneous common disease patients (n = 155), (3) drug abusers (n = 130), and (4) homosexual men (n = 187). The former two groups are considered to be low-risk groups, and the latter two, high-risk groups. The prevalence of IgG antibody on ELISA/Western blot tests for these groups were respectively: (1) 5.3%/1.8%, (2) 5.2%/1.9%, (3) 13.9%/4.6%, and (4) 4.3%/1.6% for HTLV-I, and (1) 2.7%/0.9%, (2) 4.5%/0%, (3) 12.3%/5.4%, and (4) 8.0%/5.9% for HIV-1. Instances of possible concomitant infection as shown by the presence of antibodies against both HTLV-I and HIV-1 were found only in the latter two high-risk groups, i.e. two (1.5%) in group (3), and three (1.6%) in group (4) as confirmed by both Western blot and immunofluorescence tests. Out of 97 sera collected from drug abusers in 1985-86 which had IgG antibody by Western blot test against HIV-1, 23 (23.7%) were HTLV-I antibody positive by ELISA test (Group 5), and 8 of these were confirmed by Western blot test. Among these 8 persons, IgM antibody against HTLV-I was found in 2, while that against HIV-1 was positive in 7 persons.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892.
authors.forename: K S
authors.initials: KS
authors.lastname: Chang
authors.forename: L C
authors.initials: LC
authors.lastname: Wang
authors.forename: C L
authors.initials: CL
authors.lastname: Gao
authors.forename: S
authors.initials: S
authors.lastname: Alexander
authors.forename: R C
authors.initials: RC
authors.lastname: Ting
authors.forename: A
authors.initials: A
authors.lastname: Bodner
authors.forename: T
authors.initials: T
authors.lastname: Log
authors.forename: A F
authors.initials: AF
authors.lastname: Kuo
authors.forename: P
authors.initials: P
authors.lastname: Strickland
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000453:epidemiology / Q000276:immunology; D000328:Adult; D000368:Aged; D015153:Blotting, Western / Q000379:methods; D006800:Deltaretrovirus Infections / Q000150:complications / Q000453:epidemiology / Q000276:immunology; D004219:District of Columbia; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005455:Fluorescent Antibody Technique; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies / Q000032:analysis*; D015481:HTLV-I Antibodies / Q000032:analysis*; D006716:Homosexuality; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D007075:Immunoglobulin M / Q000032:analysis*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012189:Retrospective Studies; D019966:Substance-Related Disorders / Q000276:immunology
chemical_list: D015483:HIV Antibodies; D015481:HTLV-I Antibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M